phenyl acetate has been researched along with Pulmonary Hypertension in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Clozel, M; Gatfield, J; Gnerre, C; Hess, P; Iglarz, M; Menyhart, K; Monnier, L; Morrison, K; Nayler, O; Wanner, D | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Remenova, T | 1 |
| Honorato Pérez, J | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Krause, A; Lott, D; Machacek, M | 1 |
| Calderone, A; Daneault, C; Dupuis, J; Fen Shi, Y; Gagnon, L; Grouix, B; Laurin, P; Nguyen, QT; Nsaibia, MJ; Ruiz, M; Sirois, MG; Tardif, JC | 1 |
| Knaapen, P; Lammertsma, AA; Lubberink, M; Raijmakers, P; Ruiter, G; van Campen, J; van der Laarse, WJ; Vonk Noordegraaf, A; Wong, YY | 1 |
| Lang, IM; Skoro-Sajer, N | 1 |
| Beanlands, RS; Fujii, S; Ito, YM; Kasai, K; Katoh, C; Manabe, O; Mielniczuk, L; Nishimura, M; Ohira, H; Oyama-Manabe, N; Sato, T; Tamaki, N; Tomiyama, Y; Tsujino, I; Yoshinaga, K | 1 |
| Asaki, T; Clozel, M; Gatfield, J; Hamamoto, T; Kuwano, K; Morrison, K | 1 |
| Adams, JW; Behan, DP; Blackburn, A; Boatman, PD; Chang, S; Chen, W; Chen, X; Gaidarov, I; Garrido Montalban, A; Gharbaoui, T; Kramer, B; Krishnan, A; Leakakos, T; Morgan, M; Pal, B; Ramirez, J; Sadeque, A; Sage, CR; Semple, G; Shakya, SR; Shi, Y; Shifrina, A; Shin, YJ; Shu, HH; Tran, TA; Tung, SF; Unett, DJ; Vallar, P; Zou, N | 1 |
| Hashino, A; Kosugi, K; Kuwabara, K; Kuwano, K; Noda, K | 1 |
| Clozel, M; Ernst, R; Haag, F; Kauser, K; Morrison, K; Studer, R | 1 |
| Chen, X; Cheng, D; Fan, L; Guan, J; Su, Q; Xia, X | 1 |
| Chen, XJ; Cheng, DY; Guan, J; Wang, H; Xia, XQ; Zhang, Y | 1 |
3 review(s) available for phenyl acetate and Pulmonary Hypertension
| Article | Year |
|---|---|
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Adult; Animals; Antihypertensive Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Topics: Acetamides; Acetates; Administration, Oral; Animals; Antihypertensive Agents; Drug Design; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2017 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines; Receptors, Prostaglandin; Signal Transduction | 2014 |
1 trial(s) available for phenyl acetate and Pulmonary Hypertension
| Article | Year |
|---|---|
Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
Topics: Acetamides; Acetates; Adult; Antihypertensive Agents; Bilirubin; Double-Blind Method; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Leukocyte Count; Male; Models, Biological; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazines; Treatment Outcome | 2017 |
10 other study(ies) available for phenyl acetate and Pulmonary Hypertension
| Article | Year |
|---|---|
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Topics: Acetamides; Acetates; Animals; beta-Arrestins; Cell Proliferation; CHO Cells; Contractile Proteins; Cricetinae; Cricetulus; Cyclic AMP; Epoprostenol; Extracellular Matrix; Humans; Hypertension, Pulmonary; Iloprost; Male; Muscle Contraction; Muscle Relaxation; Pyrazines; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Epoprostenol | 2017 |
PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure.
Topics: Acetates; Animals; Cells, Cultured; Disease Models, Animal; Endothelin-1; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Fibrosis; Heart Failure; Heart Ventricles; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Interleukin-6; Lung; Male; Phosphorylation; Pulmonary Fibrosis; Rats, Wistar; Receptors, G-Protein-Coupled; Signal Transduction; Transforming Growth Factor beta; Ventricular Dysfunction, Right; Ventricular Function, Right; Ventricular Remodeling | 2020 |
11C-Acetate clearance as an index of oxygen consumption of the right myocardium in idiopathic pulmonary arterial hypertension: a validation study using 15O-labeled tracers and PET.
Topics: Acetates; Adult; Aged; Blood Pressure; Carbon; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Middle Aged; Myocardium; Oxygen; Oxygen Radioisotopes; Positron-Emission Tomography; Pulmonary Artery; Radioactive Tracers | 2013 |
Attenuated right ventricular energetics evaluated using ¹¹C-acetate PET in patients with pulmonary hypertension.
Topics: Acetates; Adult; Aged; Carbon; Case-Control Studies; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals; Stroke Volume; Ventricular Function, Right | 2014 |
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Animals; CHO Cells; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cricetulus; Dogs; Double-Blind Method; Haplorhini; Humans; Hypertension, Pulmonary; Myocytes, Smooth Muscle; Platelet Aggregation Inhibitors; Pulmonary Artery; Pyrazines; Randomized Controlled Trials as Topic; Rats; Receptors, Epoprostenol; Structure-Activity Relationship | 2015 |
Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Topics: Acetates; Administration, Oral; Animals; Biological Availability; Carbamates; Drug Discovery; Hypertension, Pulmonary; Rats; Receptors, Prostaglandin; Structure-Activity Relationship | 2017 |
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active fo
Topics: Acetamides; Acetates; Animals; Antihypertensive Agents; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; In Vitro Techniques; Male; Prodrugs; Pulmonary Artery; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation | 2008 |
Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Topics: Acetamides; Acetates; Alprostadil; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Epoprostenol; Hypertension, Pulmonary; In Vitro Techniques; Male; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Receptors, Epoprostenol; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2012 |
[Preventive effects of montelukast on hypoxic pulmonary hypertension in rats].
Topics: Acetates; Animals; Cyclopropanes; Hypertension, Pulmonary; Hypoxia; Leukotriene Antagonists; Leukotriene C4; Male; Membrane Proteins; Quinolines; Random Allocation; Rats; Rats, Wistar; Receptors, Leukotriene; Sulfides | 2003 |
[Preventive effects of montelukast on the collagen expression of pulmonary arterioles in rats with chronic hypoxia].
Topics: Acetates; Animals; Arterioles; Collagen Type I; Cyclopropanes; Hypertension, Pulmonary; Hypoxia; Leukotriene Antagonists; Male; Pulmonary Artery; Quinolines; Random Allocation; Rats; Rats, Wistar; Sulfides | 2005 |